Loading
A phase 1/2 trial of Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by BioInvent International AB, active and no longer recruiting.
BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06205706 by BioInvent International AB, with 35 participants enrolled, started 2023-12-04 and due to reach its primary completion in 2027-07-14. Interventions recorded: BI-1910, Pembrolizumab. Conditions listed: Solid Tumors, Non Small Cell Lung Cancer, Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares BioInvent International, Pembrolizumab, Immune checkpoint inhibitors.
Shares BioInvent International, Pembrolizumab, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/